Immatics (NASDAQ:IMTX) Position Reduced by RTW Investments LP

RTW Investments LP decreased its position in Immatics (NASDAQ:IMTX - Free Report) by 34.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,540,540 shares of the company's stock after selling 3,459,460 shares during the quarter. RTW Investments LP owned 5.48% of Immatics worth $46,503,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in IMTX. Bank of America Corp DE raised its holdings in shares of Immatics by 166.0% during the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company's stock worth $25,000 after purchasing an additional 2,231 shares during the period. Virtus ETF Advisers LLC raised its stake in Immatics by 34.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company's stock worth $68,000 after acquiring an additional 2,479 shares during the period. Guggenheim Capital LLC bought a new position in Immatics in the fourth quarter worth about $101,000. Forefront Analytics LLC lifted its holdings in Immatics by 42.3% in the fourth quarter. Forefront Analytics LLC now owns 15,911 shares of the company's stock worth $113,000 after acquiring an additional 4,731 shares during the last quarter. Finally, Graham Capital Management L.P. acquired a new position in Immatics in the fourth quarter valued at approximately $130,000. Institutional investors and hedge funds own 64.41% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald restated an "overweight" rating on shares of Immatics in a research report on Tuesday, April 1st.

Immatics Stock Performance

Shares of IMTX traded up $0.55 during midday trading on Monday, hitting $5.29. 1,108,585 shares of the stock traded hands, compared to its average volume of 657,544. Immatics has a 1-year low of $3.30 and a 1-year high of $13.77. The firm has a market capitalization of $643.00 million, a PE ratio of -8.02 and a beta of 0.87. The business's 50 day moving average price is $4.48 and its two-hundred day moving average price is $5.82.

Immatics (NASDAQ:IMTX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.04. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. The company had revenue of $20.12 million during the quarter, compared to the consensus estimate of $14.92 million. As a group, equities research analysts forecast that Immatics will post -0.72 EPS for the current fiscal year.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.